Drug Profile
RGS 2064
Latest Information Update: 14 Sep 2015
Price :
$50
*
At a glance
- Originator Regenesance
- Class
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Brain injuries; Spinal cord injuries
Most Recent Events
- 07 Dec 2010 RGS 2064 is available for licensing as of 07 Dec 2010. http://www.regenesance.com
- 07 Dec 2010 Phase-I/II clinical trials in Brain injuries in Netherlands (unspecified route)
- 07 Dec 2010 Phase-I/II clinical trials in Spinal cord injuries in Netherlands (unspecified route)